Immuron Ltd — Board/Management Information 2012

Feb 7, 2012

==> picture [51 x 35] intentionally omitted <==

==> picture [55 x 35] intentionally omitted <==

==> picture [55 x 35] intentionally omitted <==

IMMURON APPOINTS STEWART WASHER AS A NON-EXEC DIRECTOR

Melbourne, Australia, 8 February 2012 : A u stralian bio p harmaceutical company Immuron Li m ited (ASX: I M C) has app o inted Dr St e wart Washer as a non-e x ecutive director. This a p pointment c o ntinues Immuro n ’s transfor m ation to a c o mmercially f o cused com p any.

Dr Was h er is curren t ly the invest m ent manager with IB M a nagers, a h i ghly succes s ful biotechnology fund inv e sting in clin i cal stage A u stralasian b i otech comp a nies. He is a lso a non-e x ecutive director of Healthli n x Ltd (ASX: HTX), and venture partn e r with Nestlé’s Inventag e s Fund.

Dr Was h er has considerable experience in n e gotiating su c cessful co m mercial part n erships an d license agreem e nts in Austr a lia and the r est of the w o rld. He has 15 years’ senior executi v e and board experie n ce in comm e rcial techn o logy compa n ies, medica l , food, agric u ltural and i n dustrial sectors.

He has r aised over $ 50 million in private sha r eholder and government funds to inv e st in his co m panies and wa s a founder of a $120 mill i on life scien c e fund. He was previously Chairman of R esonance H ealth Limite d and promi s ing head lic e treatment c ompany Hatchte c h Pty Ltd. D r Washer was also on t h e AusBiote c h Board and the Senate a t Murdoch University.

The ap p ointment of D r Washer c o incides wit h the expans i on of comm e rcialisation a ctivities by the compan y . In particul a r the comp a ny has agg r essive com m ercial expa n sion plans f o r its highly e ffective Travela n travellers’ d iarrhoea pr o duct.

“As ther e is increasi n g interest b y a number o f overseas c ompanies in Immuron’s N ASH/Fatty L iver product IMM124E following IND c learance b y the US FD A , Stewart’s g uidance in n egotiating p a rtnering and lice n ce transactions will be e xtremely valuable,” said Immuron’s C hairman Pr o fessor Colin Chapm a n.

“Immur o n expects t o devote con s iderable resources during the 2012 y ear in discu s sions and negotiations with multi-national pharmaceutic a l and biote c h companie s to cement l icensing agreem e nts.”

“Stewar t has worked in both pha r maceuticals and functio n al foods. H e is impresse d by Immur o n’s platform technology a nd is very e nthusiastic a bout the co m mercial potential of the p roducts in develop m ent, partic u larly for NA S H/Fatty Liv e r. “

“Today’ s changes are part of the transformati o n of the co m pany to a m uch strong e r product commercialisation f o cus led by C hief Executi v e Officer Joe Baini.”

The Bo a rd expresse s its appreci a tion for thei r contributio n s to the co m pany to bot h Professor R Robins- B rowne and Mr Simon S a llka who to d ay resigned as non-exe c utive direct o rs.

Contact

Colin Chapman Rudi Michelson +61 3 8637 1107 Monsoon Communications +61 3 9620 3333 0411 402 737

About Immuron Limited

Immuron is a biopharmaceutical company focused on oral immunotherapy treatments using dairy-derived antibody products for humans. Immuron is uniquely positioned with a versatile technology platform capable of generating a wide range of products with a high safety profile. This high safety profile makes it possible to complete pre-clinical studies relatively quickly and increases the prospect that the clinical development of Immuron’s products will be expedited. Immuron’s current products and product candidates target infectious diseases of the gastrointestinal tract, chronic diseases such as fatty liver (NASH), and the prevention of influenza. Immuron has one product in the market, Travelan, for preventing travellers’ diarrhoea. Immuron’s main scientific alliances are with Hadassah Medical Center (Israel), the University of Melbourne and Monash University (Australia).